Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries
The hexavalent vaccines DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib are routinely used for primary immunization of infants against diphtheria, tetanus, pertussis, hepatitis B virus, poliomyelitis, and Haemophilus influenzae type b. A recent publication showed that after primary immunization with these v...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-01-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2023.2202124 |
| _version_ | 1797673080141643776 |
|---|---|
| author | Marina George Jaime Pérez Martin Mohammad AbdelGhany Foteini Gkalapi Nicolas Jamet Richelle C. Kosse Yara Ruiz García Elisa Turriani Valérie Berlaimont |
| author_facet | Marina George Jaime Pérez Martin Mohammad AbdelGhany Foteini Gkalapi Nicolas Jamet Richelle C. Kosse Yara Ruiz García Elisa Turriani Valérie Berlaimont |
| author_sort | Marina George |
| collection | DOAJ |
| description | The hexavalent vaccines DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib are routinely used for primary immunization of infants against diphtheria, tetanus, pertussis, hepatitis B virus, poliomyelitis, and Haemophilus influenzae type b. A recent publication showed that after primary immunization with these vaccines, the odds ratios of adverse reactions (ARs) were significantly lower for DT3aP-HBV-IPV/Hib than for DT2aP-HBV-IPV-Hib. Our aim is to understand the impact of the various reactogenicity profiles at country level by comparing the ARs induced by one dose of DT3aP-HBV-IPV/Hib versus DT2aP-HBV-IPV-Hib in the primary infant immunization course. A mathematical projection tool was developed to simulate vaccination of infants with both vaccines in six countries: Austria, the Czech Republic, France, Jordan, Spain, and the Netherlands. Proportions of three local and five systemic ARs of interest for both vaccines were based on findings from a previous meta-analysis of ARs in infants. The absolute risk reductions calculated ranged from 3.0% (95% confidence interval [CI]: 2.8%–3.2%) for “Swelling at the injection site, any grade” to 10.0% (95% CI: 9.5%–10.5%) for “Fever, any grade.” The difference in occurrence of the AR “Fever, any grade” between vaccines in 2020 ranged from over 7,000 in Austria to over 62,000 in France. Over 5 years, this would amount to a reduction of over 150,000 ARs in Austria and over 1.4 million ARs in France when using DT3aP-HBV-IPV/Hib instead of DT2aP-HBV-IPV-Hib. In conclusion, the estimated numbers of ARs following hexavalent vaccination in six countries showed that vaccination of infants with DT3aP-HBV-IPV/Hib could lead to fewer ARs than vaccination with DT2aP-HBV-IPV-Hib. |
| first_indexed | 2024-03-11T21:39:23Z |
| format | Article |
| id | doaj.art-0710d3a285634555b5c4286dd4eefa39 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:39:23Z |
| publishDate | 2023-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-0710d3a285634555b5c4286dd4eefa392023-09-26T13:25:49ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2023-01-0119110.1080/21645515.2023.22021242202124Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countriesMarina George0Jaime Pérez Martin1Mohammad AbdelGhany2Foteini Gkalapi3Nicolas Jamet4Richelle C. Kosse5Yara Ruiz García6Elisa Turriani7Valérie Berlaimont8Hari Group LimitedMurcia Health CouncilGSKGSKGSKGSKGSKGSKGSKThe hexavalent vaccines DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib are routinely used for primary immunization of infants against diphtheria, tetanus, pertussis, hepatitis B virus, poliomyelitis, and Haemophilus influenzae type b. A recent publication showed that after primary immunization with these vaccines, the odds ratios of adverse reactions (ARs) were significantly lower for DT3aP-HBV-IPV/Hib than for DT2aP-HBV-IPV-Hib. Our aim is to understand the impact of the various reactogenicity profiles at country level by comparing the ARs induced by one dose of DT3aP-HBV-IPV/Hib versus DT2aP-HBV-IPV-Hib in the primary infant immunization course. A mathematical projection tool was developed to simulate vaccination of infants with both vaccines in six countries: Austria, the Czech Republic, France, Jordan, Spain, and the Netherlands. Proportions of three local and five systemic ARs of interest for both vaccines were based on findings from a previous meta-analysis of ARs in infants. The absolute risk reductions calculated ranged from 3.0% (95% confidence interval [CI]: 2.8%–3.2%) for “Swelling at the injection site, any grade” to 10.0% (95% CI: 9.5%–10.5%) for “Fever, any grade.” The difference in occurrence of the AR “Fever, any grade” between vaccines in 2020 ranged from over 7,000 in Austria to over 62,000 in France. Over 5 years, this would amount to a reduction of over 150,000 ARs in Austria and over 1.4 million ARs in France when using DT3aP-HBV-IPV/Hib instead of DT2aP-HBV-IPV-Hib. In conclusion, the estimated numbers of ARs following hexavalent vaccination in six countries showed that vaccination of infants with DT3aP-HBV-IPV/Hib could lead to fewer ARs than vaccination with DT2aP-HBV-IPV-Hib.http://dx.doi.org/10.1080/21645515.2023.2202124absolute risk reductionadverse reactionhexavalent vaccineinfantsreactogenicitysimulationvaccination |
| spellingShingle | Marina George Jaime Pérez Martin Mohammad AbdelGhany Foteini Gkalapi Nicolas Jamet Richelle C. Kosse Yara Ruiz García Elisa Turriani Valérie Berlaimont Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries Human Vaccines & Immunotherapeutics absolute risk reduction adverse reaction hexavalent vaccine infants reactogenicity simulation vaccination |
| title | Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries |
| title_full | Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries |
| title_fullStr | Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries |
| title_full_unstemmed | Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries |
| title_short | Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries |
| title_sort | reduced reactogenicity of primary vaccination with dt3ap hbv ipv hib compared with dt2ap hbv ipv hib among infants mathematical projections in six countries |
| topic | absolute risk reduction adverse reaction hexavalent vaccine infants reactogenicity simulation vaccination |
| url | http://dx.doi.org/10.1080/21645515.2023.2202124 |
| work_keys_str_mv | AT marinageorge reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT jaimeperezmartin reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT mohammadabdelghany reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT foteinigkalapi reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT nicolasjamet reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT richelleckosse reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT yararuizgarcia reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT elisaturriani reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries AT valerieberlaimont reducedreactogenicityofprimaryvaccinationwithdt3aphbvipvhibcomparedwithdt2aphbvipvhibamonginfantsmathematicalprojectionsinsixcountries |